Has Stephen Jensik, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,337 in general payments to Stephen Jensik, MD across 14 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stephen Jensik, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stephen Jensik, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stephen Jensik, MD

Transplant Surgery · Chicago, ILNPI 1245269869

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,169 of the $1,337 with a category attached, or 87.4%. It is spread thinly across 10 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $405 and has fallen 62.0% since, to $154 in 2025. That places this record below the midpoint for transplant surgery clinicians in IL, where the typical reported total is $2,190.

$1,337in general payments, 2019–2025

Across 14 payments — averaging $95.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Veloxis Pharmaceuticals, Inc.$253
One Lambda, Inc.$188
Lemaitre Vascular, Inc.$169
AstraZeneca$150
Laminate Medical Technologies Inc.$135
E.r. Squibb & Sons, L.L.C.$121
plus $322 from 4 others

$15,255in research payments, 2019–2025

Across 1 payment — averaging $15,255 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

E.r. Squibb & Sons, L.L.C.$15K

What the payments were for

Speaking & faculty fees$15011%
Food & beverage$1,16987%
Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Veloxis Pharmaceuticals, Inc.	3	$253
One Lambda, Inc.	1	$188
Lemaitre Vascular, Inc.	3	$169
AstraZeneca	1	$150
Laminate Medical Technologies Inc.	1	$135
E.r. Squibb & Sons, L.L.C.	1	$121
Sanofi-aventis U.S. LLC	1	$120
Takeda Pharmaceuticals U.S.A., Inc.	1	$104
Medtronic	1	$80
Merck	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,337 in reported general payments places this provider in the 45th percentile of 52 transplant surgery providers in Illinois.

See all transplant surgery providers in Illinois →

Medicare billing

Part B allowed, 2024

$50,215

Medicare patients

136

Services billed

245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Atovaquone	38	$21,350
Nifedipine ErNifedipine	64	$2,598
Valganciclovir Hcl	21	$2,439
Tacrolimus	22	$1,061
Mycophenolic AcidMycophenolate Sodium	11	$899
Rosuvastatin Calcium	15	$770
Mycophenolate Mofetil	11	$713
Tamsulosin Hcl	67	$691
Carvedilol	62	$637
Prednisone	129	$629
Pantoprazole Sodium	23	$428
Famotidine	50	$366
Finasteride	28	$304
Potassium Chloride	11	$286
Atorvastatin Calcium	36	$266

Paid to pharmacies, not to this prescriber.

Other transplant surgery in Chicago

Piotr WitkowskiChicago$235K
Vinayak RohanChicago$95K
John FungChicago$95K
Talia BakerChicago$51K
Joseph LeventhalChicago$25K
Lloyd BrownChicago$16K
Daniel Borja CachoChicago$15K
Oyedolamu OlaitanChicago$11K
Mario SpaggiariChicago$11K
Zachary DietchChicago$11K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →